		tion No.	Applicant(s)	
Notice of Allowability	09/831,720		CASELLAS ET AL.	
	Examin		Art Unit	
	Dr. Kaila	sh C. Srivastava	1651	
				<u> </u>
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.				
1. X This communication is responsive to Response filed 10/24/2003.				
2. The allowed claim(s) is/are 22, 30, 32, 38 and 42.				
3. The drawings filed on 14 May 2001 are accepted by the Examiner.				
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this national stage application from the				
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:				
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.				
(a) The translation of the foreign language provisional application has been received.				
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.				
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE				
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.				
8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.				
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached				
1) 🗌 hereto or 2) 🔲 to Paper No				
(b) 🔲 including changes required by the proposed drawing correction filed, which has been approved by the Examiner.				
(c) 🔲 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No				
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).				
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s)				
1 Notice of References Cited (PTO-892)		5 ☐ Notice of Informal Pa	tent Application (PT0)-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948)		6⊠ Interview Summary (PTO-413), Paper No. <u>0122</u> .		
3 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No	3),	7⊠ Examiner's Amendme	ent/Comment	
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	•	8⊠ Examiner's Statement 9□ Other .	t of Reasons for Allo	wance

Examiner's Amendment/Comment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR
 To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Paul E. DuPont on 02/02/2004.

In the Claims:

- Claims 16 to 21, 23 to 29,31, 33 to 37 and 39 to 41 are cancelled without prejudice or disclaimer.
- Claim 42 has been added as follows:
 - -- 42. A topical composition for treating cutaneous stress containing as active principle a substance that binds to the peripheral benzodiazepine receptor, wherein said substance is a fermentation product of *Nocardia* SRL 4988, *Streptomyces* SRL 5186 or *Actinosinnema* SRL 5189 present in an amount of from 0.00001% to 20% by weight relative to the total weight of the composition. --
- In Claim 22 at Line 1, number "21" has been replaced with --42--.
- In Claim 30 at Line 3, number "20" has been replaced with --42--.
- In Claim 38 at Line 3, "20" has been replaced with --42--.
- 2. It is noted that the microorganisms, *Nocardia* SRL 4988, *Streptomyces* SRL 5186 or *Actinosinnema* SRL 5189 required to practice the claimed invention are currently publicly available. It appears that said microorganism should remain available to the public beyond the effective life of the patent. Applicants must bring to the attention of this Office, any information to the contrary which comes to applicants' attention during the prosecution of this application.

Any comments considered necessary by applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Kailash C. Srivastava whose telephone number is (571) 272-0923. The examiner can normally be reached on Monday to Thursday from 7:30 A.M. to 6:00 P.M. (Eastern Standard or Daylight Savings Time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (571) 272-0926 Monday through Thursday. The fax phone number for the organization where this application or proceeding is assigned is (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Kailash C. Srivastava, Ph.D. Patent Examiner Art Unit 1651 (571) 272-0923

February 3, 2004

CHRISTOPHER A. TATE PRIMARY EXAMINER